Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Low-Dose IL-2 Effective in Treatment of SLE

Publish date:: April 29, 2019

Key clinical point: Low-dose recombinant interleukin-2 proved safe and effective for treatment of SLE in a randomized trial.

Major finding: The median SLEDAI score improved from 12 at baseline to 4 at week 24.

Study details: This randomized, double-blind, placebo-controlled clinical trial comprised 60 patients with SLE.

Disclosures: The presenter reported having no financial conflicts regarding her study.

Citation:

Reporting from LUPUS 2019

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Early treatment of RA with DMARDs promotes sustained remission,

Must Reads in Lupus & Connective Tissue Diseases

High-need, high-cost lupus patients described for first time,

Slow taper off antimalarial is best to avoid lupus flare during remission,

Sjögren’s symptom clusters may identify treatment options,

Transcutaneous VNS on the ear shows positive effects in lupus pilot trial,

ASSET extension supports abatacept as treatment for diffuse cutaneous systemic sclerosis,